Sagimet Biosciences Inc.
For the period ended Dec 31, 2025. Filed Mar 11, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 11, 2026
SGMT$10.83+9.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations and Comprehensive Loss
(in thousands, except for share and per share amounts)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Years Ended December 31, | ||||||
| · · 2025 · · 2024 | ||||||
| Operating expenses: | | | | | | |
| Research and development | | $39,054 | | $38,444 | ||
| General and administrative | | 17,835 | | 16,010 | ||
| Total operating expenses | | 56,889 | | 54,454 | ||
| Loss from operations | | (56,889) | | (54,454) | ||
| Other income: | | | | | | |
| Interest income and other, net | | | 5,851 | | | 8,887 |
| Total other income | | 5,851 | | 8,887 | ||
| Net loss | | $(51,038) | | $(45,567) | ||
| | | | | | | |
| Net loss per share of Series A and Series B common stock outstanding, basic and diluted | | $(1.58) | | $(1.45) | ||
| Weighted-average shares of Series A and Series B common stock outstanding, basic and diluted | | | 32,345,525 | | 31,350,725 | |
| | | | | | | |
| Net loss | | $(51,038) | | $(45,567) | ||
| Other comprehensive (loss) income: | | | | | ||
| Net unrealized (loss) gain on marketable securities | | (110) | | 200 | ||
| Total comprehensive loss | | $(51,148) | | $(45,367) | ||
STATEMENTS OF
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.